Tuberculosis: Development of New Drugs and Treatment Regimens
Downloads
Tuberculosis (TB) still becomes a public health crisis. Drug-resistant TB (DR-TB) becomes a concern as the increasing DR-TB cases in countries with high TB burden. The 2017 World Health Organization (WHO) guideline recommended a combination of TB treatment consisting of 2 months of intensive phase with isoniazid (H), rifampisin (R), pyrazinamid (Z), and ethambutol (E), followed by 4 months of continuation phase with HR daily. WHO has updated DR-TB treatment guidelines several times. In 2016, WHO recommended shorter regimen and individual regimen based on certain conditions. The most updated 2020 WHO guideline recommended the short regimen consisting of all oral drugs as well as changes in the grouping of medicines used in DR-TB regimens in longer/individual regimens. Bedaquiline, delamanid, pretomanid, and sutezolid are new drugs which have been studied for their uses as anti-TB drugs (ATD). Bedaquilin and delamanid, which have passed phase 3 trials, have been approved and recommended by WHO for DR-TB treatment. Repurposed drugs have been used for DR-TB treatment during the time of evaluation of drugs list and regimens for DR-TB treatment. Fluoroquinolones, clofazimine, linezolid, carbapenem, amoxicillin/clavulanic acid are repurposed drugs. TB and DR-TB management will be updated at any time, based on the latest findings in studies, to evaluate and improve the effectiveness of current treatments. Prevention of active TB disease by the treatment of latent TB infection (LTBI) is also a critical component of the end TB strategy by WHO. Therefore, the development of new drugs for the LTBI treatment is also needed.
Organization WH. Global Tuberculosis Report 2020. Geneva, https://www.who.int/publications/i/item/9789240013131 (2020).
Organization WH. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva, https://www.who.int/tb/features_archive/m_xdrtb_facts/en/ (2010).
Tiberi S, du Plessis N, Walzl G, et al. Tuberculosis: Progress and Advances in Development of New Drugs, Treatment Regimens, and Host-Directed Therapies. Lancet Infect Dis 2018; 18: e183–e198.
Ahmad Khan F, Salim MAH, du Cros P, et al. Effectiveness and Safety of Standardised Shorter Regimens for Multidrug-Resistant Tuberculosis: Individual Patient Data and Aggregate Data Meta-Analyses. Eur Respir J; 50. Epub ahead of print July 2017. DOI: 10.1183/13993003.00061-2017.
Hughes J, Isaakidis P, Andries A, et al. Linezolid in Drug-Resistant Tuberculosis: Haste Makes Waste. Eur Respir J 2015; 46: 1844 LP – 1846.
Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis--Advances in Development of New Drugs, Treatment Regimens, Host-Directed Therapies, and Biomarkers. Lancet Infect Dis 2016; 16: e34-46.
Tiberi S, Muñoz-Torrico M, Duarte R, et al. New Drugs and Perspectives for New Anti-Tuberculosis Regimens. Pulmonology 2018; 24: 86–98.
Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. Eur Respir J; 49. Epub ahead of print March 2017. DOI: 10.1183/13993003.02308-2016.
Organization WH. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. Geneva, https://www.who.int/publications/i/item/9789240007048 (2020).
Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment Correlates of Successful Outcomes in Pulmonary Multidrug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis. Lancet 2018; 392: 821–834.
Organization WH. Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care (2017 Update). Geneva, https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/ (2017).
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis an Off Publ Infect Dis Soc Am 2016; 63: e147–e195.
Indonesia KKR. Panduan Pelayanan Tuberkulosis Resistan Obat untuk Fasilitas Pelayanan Kesehatan. Jakarta, 2019.
Kuaban C, Noeske J, Rieder HL, et al. High Effectiveness of a 12-Month Regimen for MDR-TB Patients in Cameroon. Int J Tuberc Lung Dis Off J Int Union against Tuberc Lung Dis 2015; 19: 517–524.
Piubello A, Harouna SH, Souleymane MB, et al. High Cure Rate with Standardised Short-Course Multidrug-Resistant Tuberculosis Treatment in Niger: No Relapses. Int J Tuberc lung Dis Off J Int Union against Tuberc Lung Dis 2014; 18: 1188–1194.
Harausz E, Cox H, Rich M, et al. QTc Prolongation and Treatment of Multidrug-Resistant Tuberculosis. Int J Tuberc lung Dis Off J Int Union against Tuberc Lung Dis 2015; 19: 385–391.
Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2019; 200: e93–e142.
Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, et al. Novel Drugs against Tuberculosis: A Clinician's Perspective. Eur Respir J 2015; 45: 1119–1131.
Guglielmetti L, Le Dí» D, Veziris N, et al. Is Bedaquiline as Effective as Fluoroquinolones in the Treatment of Multidrug-Resistant Tuberculosis? Eur Respir J 2016; 48: 582 LP – 585.
Falzon D, Gandhi N, Migliori GB, et al. Resistance to Fluoroquinolones and Second-Line Injectable Drugs: Impact on Multidrug-Resistant TB Outcomes. Eur Respir J 2013; 42: 156–168.
Tiberi S, Buchanan R, Caminero JA, et al. The Challenge of the New Tuberculosis Drugs. Presse Med 2017; 46: e41–e51.
Lee M, Lee J, Carroll MW, et al. Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. N Engl J Med 2012; 367: 1508–1518.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.